AP2359A - Sulfonamide derivatives for the treatment of diseases. - Google Patents
Sulfonamide derivatives for the treatment of diseases.Info
- Publication number
- AP2359A AP2359A AP2006003669A AP2006003669A AP2359A AP 2359 A AP2359 A AP 2359A AP 2006003669 A AP2006003669 A AP 2006003669A AP 2006003669 A AP2006003669 A AP 2006003669A AP 2359 A AP2359 A AP 2359A
- Authority
- AP
- ARIPO
- Prior art keywords
- diseases
- treatment
- sulfonamide derivatives
- sulfonamide
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04290169 | 2004-01-22 | ||
GB0406387A GB0406387D0 (en) | 2004-03-22 | 2004-03-22 | Sulfonamide derivatives for the treatment of diseases |
US60026004P | 2004-08-09 | 2004-08-09 | |
PCT/IB2005/000086 WO2005080313A2 (fr) | 2004-01-22 | 2005-01-12 | Derives de sulfonamides utilises dans le traitement de maladies |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2006003669A0 AP2006003669A0 (en) | 2006-06-30 |
AP2359A true AP2359A (en) | 2012-01-30 |
Family
ID=36954179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2006003669A AP2359A (en) | 2004-01-22 | 2005-01-12 | Sulfonamide derivatives for the treatment of diseases. |
Country Status (30)
Country | Link |
---|---|
US (4) | US7244766B2 (fr) |
EP (1) | EP1708991B1 (fr) |
JP (1) | JP4020954B2 (fr) |
AP (1) | AP2359A (fr) |
AR (1) | AR047509A1 (fr) |
AT (1) | ATE375977T1 (fr) |
AU (1) | AU2005214153B2 (fr) |
BR (1) | BRPI0507085A (fr) |
CA (1) | CA2553789C (fr) |
DE (1) | DE602005002930T2 (fr) |
DK (1) | DK1708991T3 (fr) |
DO (1) | DOP2005000006A (fr) |
EA (1) | EA011167B1 (fr) |
ES (1) | ES2293530T3 (fr) |
GE (1) | GEP20094781B (fr) |
MY (1) | MY143390A (fr) |
NL (1) | NL1028087C2 (fr) |
NO (1) | NO20062983L (fr) |
NZ (1) | NZ548318A (fr) |
OA (1) | OA13362A (fr) |
PA (1) | PA8622001A1 (fr) |
PE (1) | PE20051136A1 (fr) |
PL (1) | PL1708991T3 (fr) |
PT (1) | PT1708991E (fr) |
RS (1) | RS50561B (fr) |
SI (1) | SI1708991T1 (fr) |
TW (1) | TWI341831B (fr) |
UA (1) | UA84048C2 (fr) |
UY (1) | UY28721A1 (fr) |
WO (1) | WO2005080313A2 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS50561B (sr) * | 2004-01-22 | 2010-05-07 | Pfizer Inc. | Derivati sulfonamida za lečenje bolesti |
GB0425054D0 (en) * | 2004-03-23 | 2004-12-15 | Pfizer Ltd | Formamide derivatives for the treatment of diseases |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
EP1695973A1 (fr) * | 2005-02-24 | 2006-08-30 | Neuro3D | Sel d'Ocaperidone et composition pharmaceutique le contenant. |
WO2007010356A2 (fr) * | 2005-07-18 | 2007-01-25 | Pfizer Limited | Procede pour la preparation de derives de sulfonamide |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
BRPI0614290A2 (pt) | 2005-08-08 | 2011-03-22 | Argenta Discovery Ltd | derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
ATE549337T1 (de) | 2006-04-21 | 2012-03-15 | Novartis Ag | Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten |
JP4948913B2 (ja) * | 2006-06-16 | 2012-06-06 | 上野製薬株式会社 | ナフタレンカルボン酸アミドの製造方法 |
MX2010007604A (es) | 2008-01-11 | 2010-08-02 | Novartis Ag | Pirimidinas como inhibidores de cinasa. |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
SG172444A1 (en) | 2008-12-30 | 2011-07-28 | Pulmagen Therapeutics Inflammation Ltd | Sulfonamide compounds for the treatment of respiratory disorders |
WO2010136940A1 (fr) | 2009-05-29 | 2010-12-02 | Pfizer Limited | Nouveaux agonistes du récepteur des glucocorticoïdes |
WO2010150014A1 (fr) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires |
JP5801997B2 (ja) | 2009-07-07 | 2015-10-28 | ファイザー・リミテッドPfizer Limited | 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器 |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
WO2011098746A1 (fr) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012034095A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions comme inhibiteurs de trk |
BR112013021638A2 (pt) | 2011-02-25 | 2016-08-02 | Irm Llc | "compostos inibidores de trk, seu uso e composições que os compreendem" |
WO2013021309A1 (fr) | 2011-08-11 | 2013-02-14 | Pfizer Limited | Intermédiaire et procédé de préparation d'un dérivé sulfonamide |
AU2021296221A1 (en) | 2020-06-26 | 2023-02-02 | Mylan Pharma Uk Limited | Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0659737A2 (fr) * | 1993-12-21 | 1995-06-28 | Bristol-Myers Squibb Company | Substituts pour Catécholamines utiles comme agonistes B3 |
US20020143034A1 (en) * | 1998-12-30 | 2002-10-03 | Fujisawa Pharmaceutical Co. Ltd. | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
WO2003099764A1 (fr) * | 2002-05-28 | 2003-12-04 | Theravance, Inc. | Agonistes du recepteur adrenergique $g(b)2 alcoxy aryle |
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
WO2004100950A1 (fr) * | 2003-05-15 | 2004-11-25 | Pfizer Limited | Derives de (2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)-propylphenyle utilises comme beta2 agonistes |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US143034A (en) * | 1873-09-23 | Improvement in rocking-grates | ||
US229058A (en) * | 1880-06-22 | spencer | ||
US4404224A (en) | 1981-12-02 | 1983-09-13 | American Cyanamid Company | Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals |
US4540581A (en) | 1984-01-31 | 1985-09-10 | Bristol-Myers Company | Topical nonsteroidal anti-inflammatory compositions and uses |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5264067A (en) | 1992-04-23 | 1993-11-23 | Geber Garment Technology, Inc. | Adjustable length carriage compatible for use with differing spreading table widths and types |
SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
JPH10218861A (ja) | 1997-02-04 | 1998-08-18 | Yamanouchi Pharmaceut Co Ltd | 新規なフェネタノール誘導体又はその塩 |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
BR9810456A (pt) * | 1997-06-27 | 2001-09-25 | Fujisawa Pharmaceutical Co | Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico |
US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
HRP20000765A2 (en) * | 2000-11-10 | 2002-06-30 | Pliva D D | Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release |
US7048994B2 (en) | 2001-02-23 | 2006-05-23 | Teijin Limited | Laminated polyester film and magnetic recording medium |
US20030185700A1 (en) * | 2002-03-26 | 2003-10-02 | The Japan Steel Works, Ltd. | Heat-resisting steel and method of manufacturing the same |
RS50561B (sr) * | 2004-01-22 | 2010-05-07 | Pfizer Inc. | Derivati sulfonamida za lečenje bolesti |
-
2005
- 2005-01-12 RS RSP-2007/0488A patent/RS50561B/sr unknown
- 2005-01-12 GE GEAP20059536A patent/GEP20094781B/en unknown
- 2005-01-12 DE DE602005002930T patent/DE602005002930T2/de active Active
- 2005-01-12 NZ NZ548318A patent/NZ548318A/en not_active IP Right Cessation
- 2005-01-12 PL PL05702252T patent/PL1708991T3/pl unknown
- 2005-01-12 CA CA2553789A patent/CA2553789C/fr not_active Expired - Fee Related
- 2005-01-12 ES ES05702252T patent/ES2293530T3/es active Active
- 2005-01-12 UA UAA200608227A patent/UA84048C2/ru unknown
- 2005-01-12 DK DK05702252T patent/DK1708991T3/da active
- 2005-01-12 OA OA1200600234A patent/OA13362A/en unknown
- 2005-01-12 AU AU2005214153A patent/AU2005214153B2/en not_active Ceased
- 2005-01-12 PT PT05702252T patent/PT1708991E/pt unknown
- 2005-01-12 AT AT05702252T patent/ATE375977T1/de active
- 2005-01-12 EP EP05702252A patent/EP1708991B1/fr active Active
- 2005-01-12 SI SI200530103T patent/SI1708991T1/sl unknown
- 2005-01-12 WO PCT/IB2005/000086 patent/WO2005080313A2/fr active Application Filing
- 2005-01-12 JP JP2006550327A patent/JP4020954B2/ja not_active Expired - Fee Related
- 2005-01-12 AP AP2006003669A patent/AP2359A/xx active
- 2005-01-12 BR BRPI0507085-6A patent/BRPI0507085A/pt not_active IP Right Cessation
- 2005-01-12 EA EA200601223A patent/EA011167B1/ru not_active IP Right Cessation
- 2005-01-18 MY MYPI20050197A patent/MY143390A/en unknown
- 2005-01-18 TW TW094101443A patent/TWI341831B/zh not_active IP Right Cessation
- 2005-01-19 US US11/038,452 patent/US7244766B2/en not_active Expired - Fee Related
- 2005-01-19 UY UY28721A patent/UY28721A1/es not_active Application Discontinuation
- 2005-01-20 PE PE2005000079A patent/PE20051136A1/es not_active Application Discontinuation
- 2005-01-20 DO DO2005000006A patent/DOP2005000006A/es unknown
- 2005-01-20 AR ARP050100205A patent/AR047509A1/es unknown
- 2005-01-21 PA PA20058622001A patent/PA8622001A1/es unknown
- 2005-01-21 NL NL1028087A patent/NL1028087C2/nl not_active IP Right Cessation
-
2006
- 2006-06-27 NO NO20062983A patent/NO20062983L/no not_active Application Discontinuation
-
2007
- 2007-07-03 US US11/772,995 patent/US7528170B2/en not_active Expired - Fee Related
-
2009
- 2009-04-08 US US12/420,206 patent/US7767715B2/en not_active Expired - Fee Related
-
2010
- 2010-07-01 US US12/828,762 patent/US8013019B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0659737A2 (fr) * | 1993-12-21 | 1995-06-28 | Bristol-Myers Squibb Company | Substituts pour Catécholamines utiles comme agonistes B3 |
US5776983A (en) * | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US20020143034A1 (en) * | 1998-12-30 | 2002-10-03 | Fujisawa Pharmaceutical Co. Ltd. | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
WO2003099764A1 (fr) * | 2002-05-28 | 2003-12-04 | Theravance, Inc. | Agonistes du recepteur adrenergique $g(b)2 alcoxy aryle |
WO2004100950A1 (fr) * | 2003-05-15 | 2004-11-25 | Pfizer Limited | Derives de (2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)-propylphenyle utilises comme beta2 agonistes |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2378A (en) | Sulfonamide derivatives for the treatment of diseases. | |
AP2359A (en) | Sulfonamide derivatives for the treatment of diseases. | |
LTC1830843I2 (lt) | Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai | |
IL227841A0 (en) | Dihydropyridinones for the treatment of cancer | |
IL184934A0 (en) | 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases | |
NL1028599A1 (nl) | Verbindingen voor de behandeling van ziekten. | |
PT2056804E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares | |
GB0523961D0 (en) | The treatment of ophthalmic diseases | |
EP1768656A4 (fr) | Traitement de maladies oculaires | |
GB0400802D0 (en) | Compounds for the treatment of disease | |
GB0523964D0 (en) | The treatment of ophthalmic diseases | |
IL182353A0 (en) | Methods using glycosaminoglycans for the treatment of kidney disease | |
ZA200606780B (en) | Compounds for the treatment of diseases | |
IL176564A0 (en) | Sulfonamide derivatives for the treatment of diseases | |
GB0406387D0 (en) | Sulfonamide derivatives for the treatment of diseases | |
GB0406388D0 (en) | Sulfonamide derivatives for the treatment of diseases | |
GB0425054D0 (en) | Formamide derivatives for the treatment of diseases | |
GB0425073D0 (en) | Compounds for the treatment of diseases | |
IL177531A0 (en) | Compounds for the treatment of diseases | |
GB0420867D0 (en) | Compounds for the treatment of diseases | |
GB0408297D0 (en) | Indole derivatives for the treatment of diseases | |
GB0415352D0 (en) | Compounds for the treatment of disease | |
GB0523962D0 (en) | The treatment of ophthalmic diseases | |
GB0523965D0 (en) | The treatment of ophthalmic diseases | |
GB0425064D0 (en) | Compounds useful for the treatment of diseases |